Schizophrenia and neurosurgery: systematic review and theories

Dutta, Rajeev R.; Picton, Bryce; Brown, Nolan J.; Yang, Chenyi; Lee, Maxwell; Sung, Hana; Lopez, Alexander M.; Paff, Michelle

doi:10.3171/2022.11.focus22620

Cited by 4 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DBS within schizophrenia has faced several challenges, including difficulty or failure recruiting participants 331 , ethical considerations around vulnerability 332 , and concerns about increased surgical risks in people with this disorder 333,334 . It is, therefore, critical that future DBS trials are informed by a deeper understanding of the neural circuitry of the specific symptoms or behaviors being targeted, or systems which might have broader impact.…”

Section: Fmri In Relation To Treatment: Response/resistance Mechanism...mentioning

confidence: 99%

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

Voineskos,

Hawco,

Neufeld

et al. 2024

World Psychiatry

View full text Add to dashboard Cite

Functional neuroimaging emerged with great promise and has provided fundamental insights into the neurobiology of schizophrenia. However, it has faced challenges and criticisms, most notably a lack of clinical translation. This paper provides a comprehensive review and critical summary of the literature on functional neuroimaging, in particular functional magnetic resonance imaging (fMRI), in schizophrenia. We begin by reviewing research on fMRI biomarkers in schizophrenia and the clinical high risk phase through a historical lens, moving from case‐control regional brain activation to global connectivity and advanced analytical approaches, and more recent machine learning algorithms to identify predictive neuroimaging features. Findings from fMRI studies of negative symptoms as well as of neurocognitive and social cognitive deficits are then reviewed. Functional neural markers of these symptoms and deficits may represent promising treatment targets in schizophrenia. Next, we summarize fMRI research related to antipsychotic medication, psychotherapy and psychosocial interventions, and neurostimulation, including treatment response and resistance, therapeutic mechanisms, and treatment targeting. We also review the utility of fMRI and data‐driven approaches to dissect the heterogeneity of schizophrenia, moving beyond case‐control comparisons, as well as methodological considerations and advances, including consortia and precision fMRI. Lastly, limitations and future directions of research in the field are discussed. Our comprehensive review suggests that, in order for fMRI to be clinically useful in the care of patients with schizophrenia, research should address potentially actionable clinical decisions that are routine in schizophrenia treatment, such as which antipsychotic should be prescribed or whether a given patient is likely to have persistent functional impairment. The potential clinical utility of fMRI is influenced by and must be weighed against cost and accessibility factors. Future evaluations of the utility of fMRI in prognostic and treatment response studies may consider including a health economics analysis.

show abstract

Section: Fmri In Relation To Treatment: Response/resistance Mechanism...mentioning

confidence: 99%

Functional magnetic resonance imaging in schizophrenia: current evidence, methodological advances, limitations and future directions

Voineskos,

Hawco,

Neufeld

et al. 2024

World Psychiatry

View full text Add to dashboard Cite

show abstract

“…5,6 The chronic course of this complex disease and the difficulty of treatment can place a huge burden on patients, families and society, and the disability rate is high. 7…”

Section: Introductionmentioning

confidence: 99%

“…5,6 The chronic course of this complex disease and the difficulty of treatment can place a huge burden on patients, families and society, and the disability rate is high. 7 The causes of SZ are complex and numerous. Both genetic and environmental factors influence the development of SZ.…”

Section: Introductionmentioning

confidence: 99%

Association of CTNND2 gene polymorphism with schizophrenia: Two-sample case-control study in Chinese Han population

Chen

Cui

et al. 2023

Int J Psychiatry Med

View full text Add to dashboard Cite

Objectives Genetic factors play an important role in the etiology of schizophrenia (SZ). Catenin Delta 2 (CTNND2) is one of the genes regulating neuronal development in the brain. It is unclear whether CTNND2 is involved in SZ. With the hypothesis that CTNND2 may be a risk gene for SZ, we performed a case-control association analysis to investigate if CTNND2 gene single nucleotide polymorphisms (SNPs) are implicated in SZ in a Han Chinese northern population. Materials and Methods We recruited subjects from 2010 to 2022 from the Han population of northern Henan and divided them into two case-control samples, including a discovery sample (SZ = 528 and control = 528) and replication sample (SZ = 2458 and control = 6914). Twenty-one SNPs were genotyped on the Illumina BeadStation 500G platform using GoldenGate technology and analyzed by PLINK. Positive and Negative Syndrome Scale (PANSS) was used to assess clinical symptoms. Results Rs16901943, rs7733427, and rs2168878 SNPs were associated with SZ (Chi2 = 7.484, 11.576, and 5.391, respectively, df = 1; p = 0.006, 0.00067, and 0.02, respectively) in two samples. Rs10058868 was associated with SZ in male patients in the discovery sample (Chi2 = 6.264, df = 1, p = .044). Only rs7733427 survived Bonferroni correction. Linkage disequilibrium block three haplotypes were associated with SZ in the discovery and total sample. PANSS analysis of the four SNPs implicated rs10058868 and rs2168878 with symptoms of depression and excitement, respectively, in the SZ patients. Conclusion Four SNPs were identified as being correlated with SZ. The CTNND2 gene may be involved in susceptibility to SZ.

show abstract